In Brief This Week: Abbott; Bio-Rad Laboratories; Prometheus Laboratories; GeneGo, Sigma-Aldrich; Fluidigm | GenomeWeb

NEW YORK (GenomeWeb News) – Abbott received CE Marking in the European Union for its RealTime mS9 Colorectal cancer test, a non-invasive DNA assay that detects the methylated form of Septin 9. The assay, which runs on Abbott's m2000 PCR-based molecular diagnostic system, can be used by physicians to determine if a patient should be referred for colonoscopy. The test is not available for sale in the US, the firm noted.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.